Fresenius Medical Care provides products and services to refresh renal disease patients and their kidneys. The company is one of the largest dialysis providers in the world. Its staff treats approximately 225,000 patients a year at some 2,800 dialysis clinics worldwide, 1,800 of which are based in the US. In addition to performing dialysis, Fresenius Medical Care makes dialysis machines, dialyzers, and other supplies that are sold to hospitals and clinics through internal sales efforts and independent distributors. It also offers dialysis support services including laboratory testing, renal drug distribution, and disease management programs. Fresenius SE owns a controlling stake in Fresenius Medical Care.
The firm has been a leading consolidator of dialysis treatment (renal care) operations, particularly in the US. It typically grows by opening or acquiring singular or small groups of dialysis locations in targeted regions; for example in 2009 it added about 165 new facilities. The company's renal care segment, which accounts for more than 70% of sales, relies heavily on Medicare reimbursement; Medicare's end stage renal disease (ESRD) program accounts for about half of treatment revenues in the US. To decrease this dependence, the firm is working to increase the number of privately insured patients utilizing its services.
With a majority of its operations in the US (North America accounts for about two-thirds of sales), Fresenius Medical Care is looking to expand its presence in other regions including Europe, Africa, and the Middle East. Fresenius Medical Care's expansion efforts have already made it one of the largest dialysis providers in Asia. To further cement that position, in 2010 the company agreed to purchase Asia Renal Care from Bumrungrad International to expand its operations in Taiwan, Singapore, and other Asia/Pacific countries. It also moved to expand in Japan, Korea, and Russia that year.
Fresenius Medical Care continued its growth efforts in 2011 when it acquired Dutch firm Euromedic International's dialysis business, International Dialysis Centers (IDC), for some €485 million ($647 million). The purchase gave Fresenius about 70 clinics in Central and Eastern Europe.
The firm refocused its gaze on the US market with its 2012 acquisition of Liberty Dialysis Holdings. It paid some $1.7 billion for Liberty's 260 clinics in the US operating as Liberty Dialysis and Renal Advantage. It also struck a $385 million deal to purchase American Access Care Holdings, which operates 28 vascular access centers (facilities that conduct dialysis-related surgical procedures such as radiological imaging and catheter placement); the purchase doubled Fresenius Medical Care's vascular access operations.
The company is also looking to grow by offering new dialysis products and technologies, including upgrades on its existing equipment lines. It offers customized patient-specific treatments through its UltraCare program. Other services that support the dialysis process include disease management programs for ESRD patients (provided by subsidiary KidneyTel) and laboratory testing to determine the best course of a patient's treatment (through subsidiary Spectra Laboratories).
To further broaden its operations, Fresenius Medical Care is expanding into additional areas beyond patient care and dialysis products, such as dialysis medication (drugs regulating patient mineral and blood levels) and home therapies, and the company is pursuing additional acquisitions and partnerships in those fields. For instance, in 2008 it entered drug distribution agreement with pharma companies Luitpold and Galenica to expand its therapeutic offerings. In 2010 it expanded its home care offerings by purchasing the peritoneal (abdominal) dialysis operation of Gambro; it also acquired the assets of Xcorporeal, which had home therapy devices under development.
German medical group Fresenius SE owns about 30% of Fresenius Medical Care's common stock. It also owns 100% of the company's general partner, Fresenius Medical Care Management AG, which gives it control over the company's management board. – less